Furthermore, in vitro and in vivo studies have shown that the combination of Trametinib with the PI3K inhibitor BKM120 or the CDK4/6 inhibitor LEE011 produces synergistic antitumor effects in melanoma cells harboring BRAF fusions [201]. The gene discussed is BRAF; the disease is melanoma.